A pivotal clinical study of 10,000 patients

Link to study

Cologuard improves sensitivity in colorectal cancer screening over a leading FIT.*

Clinically proven in a prospective, head-to-head, point-in-time, 90-site, pivotal study of 10,000 patients1

Sensitivity for all stages of cancer

chart: sensitivity for all stages of cancer

Sensitivity for stages I-III of cancer

chart: sensitivity for all stages of cancer

Sensitivity for high-grade dysplasia

chart: sensitivity for high-grade dysplasia

Overall specificity

chart: overall specificity

Cologuard results are based on 11 biomarkers–10 sDNA, plus hemoglobin, while FIT tests are based on hemoglobin alone

*OC FIT-CHEK, Polymedco, Inc.

These specificity measures excluded CRC and AA for both tests.

REFERENCE 1. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.